CD20

Phase 2Small molecule

TTianjin Medical University Cancer Institute and Hospital

CD20 is one of 39 small molecule programs targeting Multiple Sclerosis (MS). It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Multiple Sclerosis (MS)Not yet recruiting

TEDRecruiting

Multiple Sclerosis (MS)Phase 1

Not yet recruiting

TEDPhase 2

Recruiting

Competition

Competitive Landscape

45 competitors in TED

#DrugCompanyPhaseTrials

Farxiga

AstraZeneca

Approved

2 2

Scemblix

Novartis

Approved

1 3

Alecensa

Roche

Approved

1 4

Rituxan

Roche

Phase 3

2 5

Medrol

Pfizer

Phase 3

2 6

Calquence

AstraZeneca

Phase 3

2 7

Golytely

Bayer

Phase 3

1 8

Treanda

AAzurity Pharmaceuticals

Phase 3

1 9

Fludara

Sanofi

Phase 2

3 10

Eliquis

Bristol-Myers Squibb

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 1Not yet recruiting

Multiple Sclerosis (MS)

NCT07676266

Q3 2029

Phase 2Recruiting

TED

NCT06463691

Clinical

Trials by Indication[1]

TED1 trial

Sonrotoclax, Zanubrutinib and CD20mab in Untreated MCL Patients

Recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT06463691·30 enrolled

Multiple Sclerosis (MS)1 trial

An Exploratory Clinical Study of Anti-CD20/B-cell Maturation Antigen (BCMA) Chimeric Antigen Receptor Autologous T Cell Product (C-CAR168) in the Treatment of Autoimmune Diseases Refractory to Standard Therapy

Not yet recruiting·TThe Affiliated Hospital of Qingdao University·Phase 1·NCT07676266·18 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for CD20. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CD20 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CD20. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Tianjin Medical University Cancer Institute and Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: TTianjin Medical University Cancer Institute and Hospital

CD20

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Q3 2029

Trials by Indication[1]

TED1 trial

Multiple Sclerosis (MS)1 trial

References

Drug Info

Quick Facts

Related News